RU2011126215A - НОВЫЕ ЗАМЕЩЕННЫЕ ОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛ-4-АМИНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛЬЦИЕВЫХ КАНАЛОВ - Google Patents
НОВЫЕ ЗАМЕЩЕННЫЕ ОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛ-4-АМИНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛЬЦИЕВЫХ КАНАЛОВ Download PDFInfo
- Publication number
- RU2011126215A RU2011126215A RU2011126215/04A RU2011126215A RU2011126215A RU 2011126215 A RU2011126215 A RU 2011126215A RU 2011126215/04 A RU2011126215/04 A RU 2011126215/04A RU 2011126215 A RU2011126215 A RU 2011126215A RU 2011126215 A RU2011126215 A RU 2011126215A
- Authority
- RU
- Russia
- Prior art keywords
- pyrrol
- octahydrocyclopenta
- trifluoromethyl
- methyl
- sulfonyl
- Prior art date
Links
- 108090000312 Calcium Channels Proteins 0.000 title 1
- 102000003922 Calcium Channels Human genes 0.000 title 1
- -1 nitro, oxo, phenyl Chemical group 0.000 claims abstract 84
- 125000000217 alkyl group Chemical group 0.000 claims abstract 72
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 61
- 239000001257 hydrogen Substances 0.000 claims abstract 61
- 125000003118 aryl group Chemical group 0.000 claims abstract 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 28
- 150000001875 compounds Chemical class 0.000 claims abstract 25
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 23
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract 9
- 150000002367 halogens Chemical class 0.000 claims abstract 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 7
- 125000001424 substituent group Chemical group 0.000 claims abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 4
- 239000000651 prodrug Chemical class 0.000 claims abstract 4
- 229940002612 prodrug Drugs 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 3
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 2
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 117
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 103
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 64
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 41
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 38
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 27
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 16
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 claims 16
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 15
- HBCAQUUDOCPMTB-UHFFFAOYSA-N methyl n-tert-butylcarbamate Chemical compound COC(=O)NC(C)(C)C HBCAQUUDOCPMTB-UHFFFAOYSA-N 0.000 claims 13
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 9
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 7
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 7
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- XIMBESZRBTVIOD-UHFFFAOYSA-N piperidine-2-carboxamide Chemical compound NC(=O)C1CCCCN1 XIMBESZRBTVIOD-UHFFFAOYSA-N 0.000 claims 5
- YCPQUHCGFDFLSI-LURJTMIESA-N (2s)-2-amino-2,3-dimethylbutanamide Chemical compound CC(C)[C@](C)(N)C(N)=O YCPQUHCGFDFLSI-LURJTMIESA-N 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 2
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- YFQYYMKGKWKAMT-UHFFFAOYSA-N butan-2-yl N-tert-butylcarbamate Chemical compound C(C)(C)(C)NC(OC(C)CC)=O YFQYYMKGKWKAMT-UHFFFAOYSA-N 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- IEFOWXXDIVKICC-UHFFFAOYSA-N propyl n-tert-butylcarbamate Chemical compound CCCOC(=O)NC(C)(C)C IEFOWXXDIVKICC-UHFFFAOYSA-N 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 239000010802 sludge Substances 0.000 claims 2
- ISTGQSQWSKCNFJ-UHFFFAOYSA-N tert-butyl n-ethylcarbamate Chemical compound CCNC(=O)OC(C)(C)C ISTGQSQWSKCNFJ-UHFFFAOYSA-N 0.000 claims 2
- BJLUORNGPCXNHM-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CN=C2C(=O)NC(=O)NC2=C1 BJLUORNGPCXNHM-UHFFFAOYSA-N 0.000 claims 1
- WAUGGYPDCQZJKK-UHFFFAOYSA-N 1h-pyrrol-3-amine Chemical compound NC=1C=CNC=1 WAUGGYPDCQZJKK-UHFFFAOYSA-N 0.000 claims 1
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 claims 1
- MJPPGVVIDGQOQT-UHFFFAOYSA-N 2-bromo-5-(2-bromo-2-nitroethenyl)furan Chemical compound [O-][N+](=O)C(Br)=CC1=CC=C(Br)O1 MJPPGVVIDGQOQT-UHFFFAOYSA-N 0.000 claims 1
- NEURYOYRKPFLKH-UHFFFAOYSA-N 2-chloro-1-isocyanato-4-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC=C(N=C=O)C(Cl)=C1 NEURYOYRKPFLKH-UHFFFAOYSA-N 0.000 claims 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 125000002981 3-(trifluoromethyl)benzoyl group Chemical group FC(C=1C=C(C(=O)*)C=CC1)(F)F 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- DGOCTMPCFFWLBH-UHFFFAOYSA-N CCCC(C)C(C)(C)OC(=O)N Chemical compound CCCC(C)C(C)(C)OC(=O)N DGOCTMPCFFWLBH-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- QJVFPOMUIKCQED-UHFFFAOYSA-N cycloheptanecarboxamide Chemical compound NC(=O)C1CCCCCC1 QJVFPOMUIKCQED-UHFFFAOYSA-N 0.000 claims 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- YAYWAEXAPGFIKA-UHFFFAOYSA-N n-(1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-4-yl)acetamide Chemical compound C1NCC2C(NC(=O)C)CCC21 YAYWAEXAPGFIKA-UHFFFAOYSA-N 0.000 claims 1
- OCKCLLMPGDCTOY-UHFFFAOYSA-N n-(2-trityl-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-4-yl)acetamide Chemical compound C1C2C(NC(=O)C)CCC2CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OCKCLLMPGDCTOY-UHFFFAOYSA-N 0.000 claims 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 230000001107 psychogenic effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11799508P | 2008-11-26 | 2008-11-26 | |
| US61/117,995 | 2008-11-26 | ||
| PCT/US2009/065847 WO2010062927A2 (en) | 2008-11-26 | 2009-11-25 | Novel substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011126215A true RU2011126215A (ru) | 2013-01-10 |
Family
ID=42124348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011126215/04A RU2011126215A (ru) | 2008-11-26 | 2009-11-25 | НОВЫЕ ЗАМЕЩЕННЫЕ ОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛ-4-АМИНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛЬЦИЕВЫХ КАНАЛОВ |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8129417B2 (OSRAM) |
| EP (1) | EP2367790A2 (OSRAM) |
| JP (1) | JP2012509940A (OSRAM) |
| KR (1) | KR20110091784A (OSRAM) |
| CN (1) | CN102292319A (OSRAM) |
| AR (1) | AR074226A1 (OSRAM) |
| AU (1) | AU2009319796A1 (OSRAM) |
| BR (1) | BRPI0921184A2 (OSRAM) |
| CA (1) | CA2742350A1 (OSRAM) |
| CL (1) | CL2011001176A1 (OSRAM) |
| CO (1) | CO6382118A2 (OSRAM) |
| CR (1) | CR20110304A (OSRAM) |
| EC (1) | ECSP11011160A (OSRAM) |
| IL (1) | IL212484A0 (OSRAM) |
| MX (1) | MX2011005537A (OSRAM) |
| NZ (1) | NZ592507A (OSRAM) |
| PA (1) | PA8850301A1 (OSRAM) |
| PE (1) | PE20110833A1 (OSRAM) |
| RU (1) | RU2011126215A (OSRAM) |
| TW (1) | TW201028378A (OSRAM) |
| UY (1) | UY32261A (OSRAM) |
| WO (1) | WO2010062927A2 (OSRAM) |
| ZA (1) | ZA201103538B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA022741B1 (ru) * | 2011-06-08 | 2016-02-29 | Ле Лаборатуар Сервье | Способ синтеза и кристаллическая форма 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1н)-ил]пропокси}бензамид гидрохлорида и фармацевтические композиции, которые ее содержат |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2011126215A (ru) | 2008-11-26 | 2013-01-10 | Эбботт Лэборетриз | НОВЫЕ ЗАМЕЩЕННЫЕ ОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛ-4-АМИНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛЬЦИЕВЫХ КАНАЛОВ |
| US8691865B2 (en) | 2008-11-26 | 2014-04-08 | Abbvie Inc. | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers |
| MX2011006169A (es) * | 2008-12-12 | 2011-06-27 | Univ Vanderbilt | Inhibidores 3.3.0-biciclicos de giyt1 y metodos para hacer y utilizar los mismos. |
| WO2011115813A1 (en) * | 2010-03-18 | 2011-09-22 | Abbott Laboratories | Lactam acetamides as calcium channel blockers |
| US8796470B2 (en) | 2010-05-25 | 2014-08-05 | Abbvie Inc. | Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators |
| US8669255B2 (en) | 2011-09-29 | 2014-03-11 | Abbvie Inc. | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers |
| US8648074B2 (en) | 2011-09-29 | 2014-02-11 | Abbvie Inc. | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers |
| EP2931727A1 (en) | 2012-12-12 | 2015-10-21 | Abbvie Inc. | Diazepine derivatives useful as calcium channel blockers in the treatment of pain |
| CN107849008B (zh) * | 2015-10-13 | 2021-04-09 | 四川海思科制药有限公司 | 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途 |
| EP3681879A1 (en) * | 2017-09-11 | 2020-07-22 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
| EA202092086A1 (ru) | 2018-03-05 | 2021-02-09 | Аркус Байосайенсиз, Инк. | Ингибиторы аргиназы |
| WO2022211060A1 (ja) | 2021-04-01 | 2022-10-06 | 小野薬品工業株式会社 | Ａｂｈｄ６アンタゴニスト |
| TW202421635A (zh) | 2022-09-30 | 2024-06-01 | 日商小野藥品工業股份有限公司 | Abhd6拮抗劑 |
| JP2024052624A (ja) * | 2022-09-30 | 2024-04-11 | 小野薬品工業株式会社 | Ａｂｈｄ６アンタゴニストを含有する医薬組成物 |
| KR20240046089A (ko) | 2022-09-30 | 2024-04-08 | 오노 야꾸힝 고교 가부시키가이샤 | Abhd6 길항제를 함유하는 약학 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0278659A (ja) | 1988-09-12 | 1990-03-19 | Shionogi & Co Ltd | アザビシクロアルカン類化合物 |
| ATE269848T1 (de) | 1999-04-07 | 2004-07-15 | Univ Virginia | Calciumkanalblocker als antikrebsmittel |
| US8163769B2 (en) * | 2002-03-12 | 2012-04-24 | Abbott Laboratories | Antibacterial compounds |
| US7223754B2 (en) | 2003-03-10 | 2007-05-29 | Dynogen Pharmaceuticals, Inc. | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders |
| JP2006514964A (ja) * | 2003-03-12 | 2006-05-18 | アボット・ラボラトリーズ | 抗菌剤としてのナフチリジン誘導体 |
| US7381738B2 (en) * | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7230022B2 (en) * | 2004-02-19 | 2007-06-12 | Bristol-Myers Squibb Company | Substituted fused bicyclic amines as modulators of chemokine receptor activity |
| JP2008507543A (ja) * | 2004-07-22 | 2008-03-13 | グラクソ グループ リミテッド | 抗細菌剤 |
| DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2603876A1 (en) * | 2005-04-19 | 2006-10-26 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| EP2350002A1 (en) | 2008-10-02 | 2011-08-03 | Abbott Laboratories | Novel compounds as calcium channel blockers |
| RU2011126215A (ru) | 2008-11-26 | 2013-01-10 | Эбботт Лэборетриз | НОВЫЕ ЗАМЕЩЕННЫЕ ОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛ-4-АМИНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛЬЦИЕВЫХ КАНАЛОВ |
| MX2011006169A (es) | 2008-12-12 | 2011-06-27 | Univ Vanderbilt | Inhibidores 3.3.0-biciclicos de giyt1 y metodos para hacer y utilizar los mismos. |
-
2009
- 2009-11-25 RU RU2011126215/04A patent/RU2011126215A/ru not_active Application Discontinuation
- 2009-11-25 UY UY0001032261A patent/UY32261A/es not_active Application Discontinuation
- 2009-11-25 CA CA2742350A patent/CA2742350A1/en not_active Abandoned
- 2009-11-25 BR BRPI0921184A patent/BRPI0921184A2/pt not_active IP Right Cessation
- 2009-11-25 PA PA20098850301A patent/PA8850301A1/es unknown
- 2009-11-25 AU AU2009319796A patent/AU2009319796A1/en not_active Abandoned
- 2009-11-25 AR ARP090104557A patent/AR074226A1/es not_active Application Discontinuation
- 2009-11-25 JP JP2011538682A patent/JP2012509940A/ja active Pending
- 2009-11-25 MX MX2011005537A patent/MX2011005537A/es unknown
- 2009-11-25 WO PCT/US2009/065847 patent/WO2010062927A2/en not_active Ceased
- 2009-11-25 EP EP09764953A patent/EP2367790A2/en not_active Withdrawn
- 2009-11-25 CN CN2009801553748A patent/CN102292319A/zh active Pending
- 2009-11-25 KR KR1020117014731A patent/KR20110091784A/ko not_active Withdrawn
- 2009-11-25 US US12/625,754 patent/US8129417B2/en not_active Expired - Fee Related
- 2009-11-25 NZ NZ592507A patent/NZ592507A/xx not_active IP Right Cessation
- 2009-11-25 PE PE2011001093A patent/PE20110833A1/es not_active Application Discontinuation
- 2009-11-25 TW TW098140141A patent/TW201028378A/zh unknown
-
2011
- 2011-04-26 IL IL212484A patent/IL212484A0/en unknown
- 2011-05-13 ZA ZA2011/03538A patent/ZA201103538B/en unknown
- 2011-05-19 CL CL2011001176A patent/CL2011001176A1/es unknown
- 2011-05-27 CO CO11065858A patent/CO6382118A2/es not_active Application Discontinuation
- 2011-06-06 CR CR20110304A patent/CR20110304A/es not_active Application Discontinuation
- 2011-06-24 EC EC2011011160A patent/ECSP11011160A/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA022741B1 (ru) * | 2011-06-08 | 2016-02-29 | Ле Лаборатуар Сервье | Способ синтеза и кристаллическая форма 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1н)-ил]пропокси}бензамид гидрохлорида и фармацевтические композиции, которые ее содержат |
Also Published As
| Publication number | Publication date |
|---|---|
| AR074226A1 (es) | 2010-12-29 |
| CL2011001176A1 (es) | 2011-11-11 |
| CA2742350A1 (en) | 2010-06-03 |
| ECSP11011160A (es) | 2011-07-29 |
| EP2367790A2 (en) | 2011-09-28 |
| WO2010062927A3 (en) | 2010-07-22 |
| AU2009319796A1 (en) | 2010-06-03 |
| CO6382118A2 (es) | 2012-02-15 |
| BRPI0921184A2 (pt) | 2018-03-13 |
| US20100130558A1 (en) | 2010-05-27 |
| KR20110091784A (ko) | 2011-08-12 |
| CN102292319A (zh) | 2011-12-21 |
| CR20110304A (es) | 2011-10-27 |
| PA8850301A1 (es) | 2010-07-27 |
| AU2009319796A8 (en) | 2011-06-30 |
| NZ592507A (en) | 2013-08-30 |
| MX2011005537A (es) | 2011-06-21 |
| IL212484A0 (en) | 2011-06-30 |
| JP2012509940A (ja) | 2012-04-26 |
| WO2010062927A2 (en) | 2010-06-03 |
| TW201028378A (en) | 2010-08-01 |
| UY32261A (es) | 2010-06-30 |
| PE20110833A1 (es) | 2011-12-21 |
| ZA201103538B (en) | 2012-11-28 |
| US8129417B2 (en) | 2012-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011126215A (ru) | НОВЫЕ ЗАМЕЩЕННЫЕ ОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛ-4-АМИНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛЬЦИЕВЫХ КАНАЛОВ | |
| JP2012509940A5 (OSRAM) | ||
| AU2002337277B2 (en) | Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain | |
| SK145398A3 (en) | Pyrazinone thrombin inhibitors | |
| RU2009129119A (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| CN104837810B (zh) | 氯胺酮衍生物 | |
| TWI591058B (zh) | ［３－（１－（１ｈ－咪唑－４－基）乙基）－２－甲基苯基］甲醇之酯類前藥 | |
| JP5453312B2 (ja) | アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択性モジュレーターである置換アリール‐（イミダゾール）‐メチル）‐フェニル化合物 | |
| JP7410950B2 (ja) | 置換アリールメチル尿素およびヘテロアリールメチル尿素、その類似体、ならびにそれらを使用する方法 | |
| JP7567041B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての新規な構造の化合物およびこれを含む薬剤学的組成物 | |
| RU2005111589A (ru) | Производные 1-пиридин-4-илмочевины | |
| RU2011149635A (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаина | |
| ES2359104T3 (es) | Derivados de tiadiazol para el tratamiento de enfermedades neurodegenerativas. | |
| CN105263924B (zh) | Cxcr7受体调节剂 | |
| JP2006504738A (ja) | Ｌ型カルシウムチャンネルを遮断し、かつホスホジエステラーゼ３型活性を阻害する同時能力を有するジヒドロピリジン化合物 | |
| JP2024041835A (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| CN115916766A (zh) | 新型吡唑衍生物 | |
| JP2003532714A (ja) | ５−ｈｔ７レセプターアンタゴニスト | |
| MX2011002945A (es) | Derivado de aminoacido. | |
| RU2011139287A (ru) | Оксииндольные производные, обладающие агонистической активностью в отношении мотилинового рецептора | |
| CA2831025A1 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
| HUP0402357A2 (hu) | Antihisztaminok alkalmazása megnövelt koponyán belüli nyomás akut csökkentésére és gyógyszerkészítmények előállítására | |
| CN1555261A (zh) | 抗血栓药和吡唑啉酮衍生物的组合药物 | |
| JP2003505414A (ja) | Ｃｎａおよび眼疾患におけるアゼチジン化合物 | |
| JP2003505418A (ja) | Ｃｎｓ障害の処置のためのアゼチジンカルボキサミド誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140404 |